*Corresponding author:Michael AB Naafs, Internist-endocrinologist with a long clinical career in internal medicine and endocrinology, Naafs International Health Consultancy, Europe
Received: July 30, 2018; Published: August 06, 2018
To view the Full Article Peer-reviewed Article PDF
Bringing the antimicrobial peptides, AMPs, in pharmaceutical business was a long process with many technical hurdles after their discovery more than 30 years ago. Structure, classification and mode of action of the AMPs as well as the selection of AMPs for clinical use are discussed. The preclinical and clinical trial results in phase 1 and phase 2 studies are discussed for 9 AMPS. These results are encouraging for the future of the AMPs as alternative antibiotics.
Abbreviations: AMPs: Antimicrobial Peptides; LPS: Lipopolysaccharides; MIC: Minimum Inhibitory Concentration; MDR: Multidrug Resistance; CFDA: China Food and Drug Administration; IDRs: Innate Defense Regulators